MiNK Therapeutics, Inc.

Item 5. Other Information.

Trading Plans of Our Directors and Officers

During the quarter ended March 31, 2025, none of our directors or executive officers adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each item is defined in Item 408 of Regulation S-K.

Nasdaq MVLS Notice

On May 13, 2025, we received a letter (the “MVLS Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying us that for the previous 30 consecutive trading days our Minimum Value of Listed Securities (“MVLS”) was less than $35.0 million, as required by Nasdaq Listing Rule 5550(b)(2) (the “MVLS Rule”). Nasdaq has provided us with 180 calendar days, or until November 10, 2025, to regain compliance. To regain compliance, our MVLS must meet or exceed $35.0 million for a minimum of ten consecutive trading days.

In the event we do not regain compliance with the MVLS Rule prior to the expiration of the compliance period, we will receive written notification that our securities are subject to delisting. At that time, we may appeal the delisting determination to a Hearings Panel. We will continue to monitor our MVLS and consider our available options to regain compliance with the MVLS Rule. However, there can be no assurance that we will be able to regain compliance with the MVLS Rule.